Sixth Wave Presents Affinity Extraction Technology at the Premiere Gathering of North America Cannabis Entrepreneurs

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") announces the Company is participating in the Benzinga Cannabis Capital Conference hosted live and virtually on October 15, 2021. Dr. Jonathan Gluckman (CEO) will speak during the Conference's Virtual Track on Thursday, October 14, 2021, at 3:20 p.m. EST.

A link to Dr. Gluckman's pre-recorded presentation is now available on Sixth Wave's Website at https://www.sixthwave.com.

The Benzinga Cannabis Capital Conference in New York City is the premier North American gathering of cannabis entrepreneurs and investors held during a 2-Day Hybrid Event on October 14-15. The event will feature an interactive forum of live and On-Demand presentations from top CEOs, investors, and leaders in the cannabis space. Event registration is available at https://www.benzinga.com/events/cannabis/october-2021.

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system and IXOS^®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop, and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our website at: https://www.sixthwave.com/.

ON BEHALF OF THE BOARD OF DIRECTORS
"Jonathan Gluckman"
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Investor Relations:
Mark MacDonald
mark@sixthwave.com
902-489-7273

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99692

News Provided by Newsfile via QuoteMedia

Sixth Wave Innovations CSE:SIXW Life Science Investing

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report the interim data analysis from the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial). The trial is investigating the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the standard-of-care chemotherapy regimen of gemcitabine and Abraxane®. Data cut-off for the interim analysis is 27 September 2024.

Keep reading...Show less

Sixth Wave Presents Affinity Extraction Technology at the Premiere Gathering of North America Cannabis Entrepreneurs

Latest News

Latest Press Releases

Related News

TOP STOCKS